RT Journal Article SR Electronic T1 Monoallelic CRMP1 gene variants cause neurodevelopmental disorder JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.07.05.22276556 DO 10.1101/2022.07.05.22276556 A1 Ethiraj Ravindran A1 Nobuto Arashiki A1 Lena-Luise Becker A1 Kohtaro Takizawa A1 Jonathan Lévy A1 Thomas Rambaud A1 Konstantin L. Makridis A1 Yoshio Goshima A1 Na Li A1 Maaike Vreeburg A1 Bénédicte Demeer A1 Achim Dickmanns A1 Alexander P.A Stegmann A1 Hao Hu A1 Fumio Nakamura A1 Angela M. Kaindl YR 2022 UL http://medrxiv.org/content/early/2022/07/06/2022.07.05.22276556.abstract AB Collapsing response mediator proteins (CRMPs) are key for brain development and function. Here, we link CRMP1 to a neurodevelopmental disorder. We report heterozygous de novo variants in the CRMP1 gene in three unrelated individuals with muscular hypotonia, intellectual disability and/or autism spectrum disorder. Based on in silico analysis these variants are predicted to affect the CRMP1 structure. We further analyzed the effect of the variants on the protein structure/levels and cellular processes. We showed that the human CRMP1 variants are dominant-negative and impact the oligomerization of CRMP1 proteins. Moreover, overexpression of mutant-CRMP1 variants affect neurite outgrowth of murine cortical neurons. While altered CRMP1 levels have been reported in psychiatric diseases, genetic mutation in CRMP1 gene has never been linked to human disease. We report for the first-time mutations in the CRMP1 gene and emphasize its key role in brain development and function by linking directly to a human neurodevelopmental disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the funding resources for this study: German Research Foundation (SFB665, SFB1315, FOR3004, AMK), the Sonnenfeld Stiftung (AMK, KLM), the Berlin Institute of Health (BIH, CRG1, AMK), the Charite (AMK, ER, LLB, KLM), and by grants-in-aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (16K07062) (FN).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all parents of the patients to participate in this study and publish the data of this research work. The human study adhered to the World Health Association Declaration of Helsinki (2013) and was approved by the local ethics committees of the Charite (approval no. EA1/212/08).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll methods applied in this project are described in detail in the ‘Materials and Methods’section and the original data are presented as source file